Literature DB >> 24514091

Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.

Marieta McGrath1, Nico C Gey van Pittius, Frederick A Sirgel, Paul D Van Helden, Robin M Warren.   

Abstract

Moxifloxacin-resistant Mycobacterium tuberculosis mutants were selected in vitro using different concentrations of moxifloxacin. gyrA mutations at codons 88 and 94 were associated with resistance (defined as an MIC of ≥2 μg/ml) (P < 0.0001 and P = 0.0053, respectively). Despite the presence of gyrA mutations, moxifloxacin significantly impedes bacterial growth, supporting its use for the treatment of ofloxacin-resistant M. tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24514091      PMCID： PMC3993264          DOI： 10.1128/AAC.02583-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

2.  Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?

Authors:  Katerina Manika; Kalliopi Chatzika; Konstantinos Zarogoulidis; Ioannis Kioumis
Journal:  Eur Respir J       Date:  2012-10       Impact factor: 16.671

3.  Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone.

Authors:  Jun-ichiro Sekiguchi; Areeya Disratthakit; Shinji Maeda; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

4.  Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.

Authors:  Elena Yu Nosova; Anastasia A Bukatina; Yulia D Isaeva; Marina V Makarova; Ksenia Yu Galkina; Arkadyi M Moroz
Journal:  J Med Microbiol       Date:  2012-09-27       Impact factor: 2.472

5.  Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.

Authors:  Amy Sarah Ginsburg; Ronggai Sun; Heather Calamita; Cherise P Scott; William R Bishai; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv.

Authors:  G P Morlock; B B Plikaytis; J T Crawford
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

Authors:  Frederick A Sirgel; Robin M Warren; Elizabeth M Streicher; Thomas C Victor; Paul D van Helden; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2012-02-22       Impact factor: 5.790

8.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.

Authors:  Marcus B Conde; Anne Efron; Carla Loredo; Gilvan R Muzy De Souza; Nadja P Graça; Michelle C Cezar; Malathi Ram; Mohammad A Chaudhary; William R Bishai; Afranio L Kritski; Richard E Chaisson
Journal:  Lancet       Date:  2009-04-04       Impact factor: 79.321

9.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.

Authors:  Deepak Almeida; Eric Nuermberger; Sandeep Tyagi; William R Bishai; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191
View more
  7 in total

1.  Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.

Authors:  Hyun Lee; Soohyun Ahn; Na Young Hwang; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Chang-Ki Kim; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Revisiting Activation of and Mechanism of Resistance to Compound IQG-607 in Mycobacterium tuberculosis.

Authors:  Bruno L Abbadi; Anne D Villela; Valnês S Rodrigues-Junior; Fernanda T Subtil; Pedro F Dalberto; Ana P S Pinheiro; Diógenes S Santos; Pablo Machado; Luiz A Basso; Cristiano V Bizarro
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis.

Authors:  Marva Seifert; Sophia B Georghiou; Richard S Garfein; Donald Catanzaro; Timothy C Rodwell
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

4.  Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance.

Authors:  Fernanda Maruri; Yan Guo; Amondrea Blackman; Yuri F van der Heijden; Peter F Rebeiro; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

5.  Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  Xia Yu; Guirong Wang; Suting Chen; Guomei Wei; Yuanyuan Shang; Lingling Dong; Thomas Schön; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Claudio U Köser; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 6.  Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy.

Authors:  Andrej Trauner; Sonia Borrell; Klaus Reither; Sebastien Gagneux
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

7.  OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.

Authors:  Norimitsu Hariguchi; Xiuhao Chen; Yohei Hayashi; Yoshikazu Kawano; Mamoru Fujiwara; Miki Matsuba; Hiroshi Shimizu; Yoshio Ohba; Izuru Nakamura; Ryuki Kitamoto; Toshio Shinohara; Yukitaka Uematsu; Shunpei Ishikawa; Motohiro Itotani; Yoshikazu Haraguchi; Isao Takemura; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.